Baxter International (BAX) recently landed in the spotlight after announcing a sharp cut to its quarterly dividend and lowering its annual sales growth outlook. These moves are tied to ongoing operational challenges and cash flow priorities.

At the same time, the company faces multiple class action lawsuits alleging that it concealed defects in its Novum LVP infusion pump. This led to a suspension of new sales for the device and fresh worries about long-term financial and reputational impacts.

Heightened concerns around litigation, product safety, and operational setbacks have left a visible mark on Baxter International’s stock this year. The company’s share price has declined sharply, resulting in a year-to-date return of -36.88% and a one-year total shareholder return of -40.89%. While management hopes recent belt-tightening will stabilize the business, momentum has clearly faded and uncertainty still dominates the outlook.

If you’re keeping tabs on shifting fortunes in healthcare, this is an opportune moment to uncover other names in the sector. See the full list for free with our curated See the full list for free..

With Baxter shares now trading at a steep discount to analyst targets and negative sentiment dominating the headlines, investors are left to consider if the recent plunge has overshot fundamentals or if future challenges are already priced in.

Most Popular Narrative: 23% Undervalued

According to the most widely tracked narrative, Baxter International’s current share price of $18.47 sits well below its assessed fair value. The gap between the last close and narrative valuation reflects both deep skepticism and bullish potential for a turnaround.

Baxter's strengthened focus on innovation, including new product launches in advanced infusion systems, AI-enabled devices, and compounding, aligns with growing demand for efficient, digitalized, and connected healthcare equipment. This positions the company to capture higher-margin revenue streams and gain market share. An aging population and the rising prevalence of chronic diseases are long-term drivers of increased demand for Baxter's critical care, compounding, and advanced surgery products. These factors support sustained top-line growth as demographic shifts accelerate healthcare utilization.

Curious which financial forecasts and future profit margins power this optimistic price? The narrative hinges on bold assumptions about innovation, market leadership, and dramatic earnings improvement. See exactly which expectations set this fair value apart from the crowd.

Result: Fair Value of $24.07 (UNDERVALUED)

However, continuing quality concerns around infusion pumps and persistent softness in hospital fluid demand could derail Baxter’s recovery and challenge the bullish narrative.

Build Your Own Baxter International Narrative

If you want to dig into the numbers or craft a different perspective, you can build your own take on Baxter's outlook in just a few minutes. Do it your way.

A great starting point for your Baxter International research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.

Looking for More Smart Investment Opportunities?

Don’t let untapped opportunities pass you by. These hand-picked ideas could reshape your portfolio’s future. Use the Simply Wall St Screener and gain an edge before the crowd.

• Boost your passive income by zeroing in on reliable companies through these 16 dividend stocks with yields > 3% that consistently deliver strong dividend yields and financial resilience.
• Supercharge your growth strategy by tapping into artificial intelligence trends with these 24 AI penny stocks featuring innovative businesses making AI breakthroughs a reality.
• Capitalize on hidden value by targeting potential bargains with these 878 undervalued stocks based on cash flows to uncover stocks trading below their calculated intrinsic worth.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.